Physiol. Genomics Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiol. Genomics 12: 73-78, 2003. First published November 12, 2002; doi:10.1152/physiolgenomics.00113.2002
1094-8341/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
12/2/73    most recent
00113.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seda, O.
Right arrow Articles by Kren, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seda, O.
Right arrow Articles by Kren, V.
Received 3 September 2002; accepted in final form 6 November 2002.
Physiological Genomics 12:73-78 (2003)
1094-8341/03 $5.00 © 2003 American Physiological Society

Rosiglitazone fails to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain

Ondrej Seda1,2, Ludmila Kazdova2, Drahomira Krenova1 and Vladimir Kren1,3

1 Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University
2 Institute for Clinical and Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic
3 Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

The favorable metabolic effects of thiazolidinediones are supposedly related to the peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma})-driven changes in lipid metabolism, particularly in free fatty acid (FFA) trafficking. The fatty acid translocase CD36 is one of the proposed PPAR{gamma} targets to mediate this action. We assessed the effect of rosiglitazone (RSG, Avandia) administration in two inbred rat strains, BN/Cub and BN.SHR4 congenic strain, differing in 10 cM proximal segment of chromosome 4. Rats were fed high-sucrose diet with or without RSG for 1 wk. In BN.SHR4, which carries defective Cd36 allele of SHR origin, RSG failed to improve glucose tolerance (assessed by the oral glucose tolerance test), did not lower triglyceridemia, nor induced increases in epididymal and retroperitoneal adipose tissue weights and adipose tissue glucose utilization, effects observed in BN/Cub. On the other hand, the RSG-treated BN.SHR4 showed lower concentrations of FFA and substantial increase in glycogen synthesis and glucose oxidation in skeletal muscle. Altogether, these results support involvement of CD36 in RSG action, suggesting this pharmacogenetic interaction may be of particular importance in CD36-deficient humans.

thiazolidinediones; fatty acid translocase; insulin resistance




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Sedova, O. Seda, L. Kazdova, B. Chylikova, P. Hamet, J. Tremblay, V. Kren, and D. Krenova
Sucrose feeding during pregnancy and lactation elicits distinct metabolic response in offspring of an inbred genetic model of metabolic syndrome
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1318 - E1324.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken
Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats
J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. M. Al-Rasheed, R. S. Chana, R. J. Baines, G. B. Willars, and N. J. Brunskill
Ligand-independent Activation of Peroxisome Proliferator-activated Receptor-{gamma} by Insulin and C-peptide in Kidney Proximal Tubular Cells: DEPENDENT ON PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY
J. Biol. Chem., November 26, 2004; 279(48): 49747 - 49754.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Heron-Milhavet, M. Haluzik, S. Yakar, O. Gavrilova, S. Pack, W. C. Jou, A. Ibrahimi, H. Kim, D. Hunt, D. Yau, et al.
Muscle-Specific Overexpression of CD36 Reverses the Insulin Resistance and Diabetes of MKR Mice
Endocrinology, October 1, 2004; 145(10): 4667 - 4676.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
M. P. Printz, M. Jirout, R. Jaworski, A. Alemayehu, and V. Kren
Genetic Models in Applied Physiology: Invited Review: HXB/BXH rat recombinant inbred strain platform: a newly enhanced tool for cardiovascular, behavioral, and developmental genetics and genomics
J Appl Physiol, June 1, 2003; 94(6): 2510 - 2522.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online